Evidence
Front Public Health. 2024 Apr 4;12:1322460. doi: 10.3389/fpubh.2024.1322460. eCollection 2024.
ABSTRACT
Chronic liver disease is a leading cause of death in the US and is often preventable. Rising burden, cost, and fatality due to liver disease are driven by intensified alcohol use in the US population and the contributions of comorbid conditions. This mini-review focuses on the topic of liver health in the context of chronic, behavioral cofactors of disease, using research-based examples from the Brown University Center for Addiction and Disease Risk Exacerbation (CADRE). Our aim is to illustrate the current challenges and opportunities in clinical research addressing liver health in the context of behavioral and medical comorbidity and to highlight next steps in this crucial area of public health research and clinical care.
PMID:38638470 | PMC:PMC11024463 | DOI:10.3389/fpubh.2024.1322460
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Alcohol-associated liver disease and behavioral and medical cofactors: unmet needs and opportunities
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- The gut-liver axis in fatty liver disease: role played by natural products
- Primary versus secondary psychosis in a patient with congenital liver disease
- Primary versus secondary psychosis in a patient with congenital liver disease
- New nomenclature for fatty liver disease
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Coexistence of metabolic-associated fatty liver disease and autoimmune or toxic liver disease
- Integrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder
- Independent Associations of Aortic Calcification with Cirrhosis and Liver Related Mortality in Veterans with Chronic Liver Disease
- The role and mechanism of SUMO modification in liver disease
- Role of lactate and lactate metabolism in liver diseases (Review)
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma
- Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity
- Spatial genomics: mapping human steatotic liver disease
- Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation
- Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation
- Research advances in serum chitinase-3-like protein 1 in liver fibrosis
- Research advances in serum chitinase-3-like protein 1 in liver fibrosis
- Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives
- FGL1 and FGL2: emerging regulators of liver health and disease
- Recurrence of Primary Disease After Adult Liver Transplant - Risk Factors, Early Diagnosis, Management, and Prevention
- Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD)
- Epidemiology, screening, and Co-management of type 2 diabetes mellitus and Metabolic-dysfunction associated steatotic liver disease
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Mast cells and the gut-liver Axis: Implications for liver disease progression and therapy
- Liver cirrhosis in a patient with alcohol dependence and autoimmune hepatitis
- Risk of mortality among patients with alcohol-associated hepatitis in the US from 2007 to 2021
- Risk of mortality among patients with alcohol-associated hepatitis in the US from 2007 to 2021
- Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies
- Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement
- The roles and potential mechanisms of plant polysaccharides in liver diseases: a review
- The Role of Cytokines in the Pathogenesis and Treatment of Alcoholic Liver Disease
- Management of Cardiovascular Risk in the Non-alcoholic Fatty Liver Disease Setting
- Spleen volume is independently associated with non-alcoholic fatty liver disease, liver volume and liver fibrosis
- Alcoholic Liver Disease in China: A Disease Influenced by Complex Social Factors That Should Not Be Neglected
- Metabolic Dysfunction-associated Fatty Liver Disease: An Urgent Call for Global Action
- The evolution of the liver transplant candidate
- Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
- Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
- AMPED study: Protocol for a randomized controlled trial of different doses of aerobic exercise training
- Ocular manifestations of liver disease: an important diagnostic aid
- Ocular manifestations of liver disease: an important diagnostic aid
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Clinical status and challenges of new drugs for metabolic dysfunction-associated fatty liver disease
- Angiocrine signaling in sinusoidal homeostasis and liver diseases
- From non-alcoholic fatty liver disease to metabolic-associated steatotic liver disease: Rationale and implications for the new terminology
- Development of an alcoholic liver disease model for drug evaluation from human induced pluripotent stem cell-derived liver organoids
- Development of an alcoholic liver disease model for drug evaluation from human induced pluripotent stem cell-derived liver organoids
- Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)
- Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)
- MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD
- Burden of liver cancer attributable to high fasting plasma glucose: a global analysis based on the global burden of disease study 2019
- Burden of liver cancer attributable to high fasting plasma glucose: a global analysis based on the global burden of disease study 2019
- Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment
- Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities
- Alcohol-associated liver disease and public health policies
- Alcohol, No Ordinary Commodity: policy implications for Canada
- Feasibility of multiorgan risk prediction with routinely collected diagnostics: a prospective cohort study in the UK Biobank
- Progress of mesenchymal stem cells (MSCs) & MSC-Exosomes combined with drugs intervention in liver fibrosis
- Hospital admissions for chronic liver diseases: a temporal study in the South Region of Brazil
- Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD
- Liver as a new target organ in Alzheimer's disease: insight from cholesterol metabolism and its role in amyloid-beta clearance
- Recruitment or activation of mast cells in the liver aggravates the accumulation of fibrosis in carbon tetrachloride-induced liver injury
Evidence Blueprint
Alcohol-associated liver disease and behavioral and medical cofactors: unmet needs and opportunities
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Alcohol-associated liver disease and behavioral and medical cofactors: unmet needs and opportunities
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- Occult liver disease: a multinational perspective
- The gut-liver axis in fatty liver disease: role played by natural products
- Fatty liver disease's renaming impacts on drug clinical trials
- Alcohol-Related liver disease: A global perspective
- Targeting Protein Phosphatases for the Treatment of Chronic Liver Disease
- Omega-3 intake is associated with liver disease protection
- Cause-specific mortality in patients with alcohol-related liver disease in Denmark: a population-based study
- Primary versus secondary psychosis in a patient with congenital liver disease
- Primary versus secondary psychosis in a patient with congenital liver disease
- COVID-19 in Individuals with Chronic Liver Diseases
- New nomenclature for fatty liver disease
- Chronic liver disease and management with silymarin: an introductory review of a clinical case collection
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Liver disease mortality and hospitalisations among people with type 2 diabetes mellitus: A population-based study
- Coexistence of metabolic-associated fatty liver disease and autoimmune or toxic liver disease
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- The effect of liver disease on hepatic microenvironment and implications for immune therapy
- Hormone action and liver disease, a complex interplay
- Integrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder
- Independent Associations of Aortic Calcification with Cirrhosis and Liver Related Mortality in Veterans with Chronic Liver Disease
- The role and mechanism of SUMO modification in liver disease
- New Insights into Nutrition and Gut-Liver Axis: A Focus on Non-Alcoholic Fatty Liver Disease
- Metabolic Dysfunction-Associated Steatotic Liver Disease: A State-of-the-Art Review
- Role of lactate and lactate metabolism in liver diseases (Review)
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma
- Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity
- Liver involvement in presence of heart disease and heart involvement in presence of liver disease: a conundrum
- Spatial genomics: mapping human steatotic liver disease
- Nonalcoholic Fatty Liver Disease as a Systemic Disease and the Need for Multidisciplinary Care
- The double roles of T cell-mediated immune response in the progression of MASLD
- The role of Sirtuin 2 in liver - An extensive and complex biological process
- Health status of patients with liver transplantation by alcohol-related disease vs another etiology: a cohort study
- Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation
- Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation
- Therapeutic potential of oleanolic acid in liver diseases
- Research advances in serum chitinase-3-like protein 1 in liver fibrosis
- Research advances in serum chitinase-3-like protein 1 in liver fibrosis
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives
- Epidemiological characteristics of inpatients with liver failure at the Beijing You'an Hospital from 2012 to 2021
- FGL1 and FGL2: emerging regulators of liver health and disease
- Recurrence of Primary Disease After Adult Liver Transplant - Risk Factors, Early Diagnosis, Management, and Prevention
- Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- The epidemiological characteristics of liver disease in hospitalized children: a 10-year single-center retrospective study
- The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD)
- Hepatocellular carcinoma surveillance - utilization, barriers and the impact of changing aetiology
- Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
- Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases
- Influence of chronic liver diseases on the course and outcome of COVID-19
- Alcoholic liver disease - 2023
- Portal vein congestion index in patients with and without chronic liver disease
- Epidemiology, screening, and Co-management of type 2 diabetes mellitus and Metabolic-dysfunction associated steatotic liver disease
- Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies
- Corrected and republished from: Metabolic associated liver disease
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Integrated care models for co-occurring alcohol use disorders and alcohol-associated liver disease in rural communities: Telehealth considerations and opportunities
- Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
- Preventive hepatology at AIIMS Rishikesh: Delivering comprehensive and integrated care for liver diseases in Northern state of India
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- Mast cells and the gut-liver Axis: Implications for liver disease progression and therapy
- Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease
- Multiple Dimensions of using Mesenchymal Stem Cells for Treating Liver Diseases: From Bench to Beside
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices